MedTrace Logo

Pharmacokinetics Study of Antitumor B in Healthy Volunteers

NCT04230057 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2020-11-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the single-dose oral pharmacokinetics of an herbal supplement - Antitumor B - in healthy subjects.

Conditions

  • Healthy Adults

Interventions

DIETARY_SUPPLEMENT

Antitumor B

Single dose 2400 mg

Sponsors & Collaborators

  • University of Houston

    lead OTHER

Principal Investigators

  • Ming Hu, PhD · University of Houston

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-12
Primary Completion
2020-01-21
Completion
2021-08-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04230057 on ClinicalTrials.gov